A recently published clinical trial shows that transitioning from traditional salbutamol relievers to a combination inhaler (budesonide–formoterol) can reduce asthma attacks by up to 45% in children ages 5–15. The study also found no adverse impact on lung function or growth and highlighted a favorable safety profile compared to older treatments.
Clinical Importance:
• Offers actionable insights for clinicians treating childhood asthma.
• Reinforces use of combination inhalers as first-line therapy for persistent symptoms.
• Supports updating clinical protocols in allergy and pulmonary clinics.
👉 This evidence adds to growing research on optimizing asthma care in pediatric populations.
No comment